Published in Oncology Business Week, June 22nd, 2008
"Where the current MTA product is aimed at the open liver surgery market, our new 1.8mm device will extend large volume microwave coagulation therapy into the lung and bone cancer arenas." said Stuart McIntyre, CEO of Acculis Limited. "In the hands of interventional radiologists as well as surgical oncologists this product will allow minimally invasive procedures to be delivered where the precision,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week